Patient Enrolment Completed for INSIGHT-003

Immutep Limited (ASX: IMM; NASDAQ: IMMP), a biotechnology company focusing on LAG-3 immunotherapies, announced the completion of patient enrolment for the INSIGHT-003 trial. This multi-centre study aims to evaluate the efficacy of eftilagimod alpha (efti) combined with pembrolizumab (KEYTRUDA®) and chemotherapy in treating advanced or metastatic non-squamous non-small cell lung cancer (1L NSCLC). The trial, primarily conducted by the Frankfurt Institute of Clinical Cancer Research IKF and other German clinical sites, successfully enrolled approximately 50 evaluable patients.

Data from the trial's first overall survival (OS) analysis were shared on November 14, 2024, with findings indicating a median OS of 32.9 months for patients, along with a remarkable 24-month OS rate of 81%. These results significantly outperform existing data from comparable treatment groups, which reported a median OS of only 22 months and a 24-month OS rate of 45.5%.

INSIGHT-003 represents the third arm of the broader Phase I INSIGHT trial, with the lead investigator Prof. Dr. Salah-Eddin Al-Batran overseeing the study. It explores the safety, tolerability, and initial efficacy of subcutaneously administered efti alongside intravenous chemotherapy (carboplatin and pemetrexed) and the PD-1 inhibitor pembrolizumab.

Further data updates from INSIGHT-003 are anticipated in 2025 and beyond, as Immutep continues to focus on leveraging its expertise in LAG-3 to develop innovative treatment options and enhance shareholder value. For more details on the trial, interested parties can visit clinicaltrials.gov (NCT03252938).

As Immutep Limited (ASX: IMM; NASDAQ: IMMP) completes patient enrolment for its INSIGHT-003 trial, the market anticipates further developments that could significantly influence the company's stock performance and shareholder value. The trial's objective—to evaluate the efficacy of eftilagimod alpha (efti) in combination with pembrolizumab and chemotherapy for treating non-small cell lung cancer (NSCLC)—marks a pivotal moment for Immutep, especially given its favourable preliminary results.

The reported median overall survival (OS) of 32.9 months for mature data, significantly outpacing the historical standard of care, positions Immutep favorably within the competitive oncology landscape. The heightened OS rate suggests the potential for efti to become a valuable addition in first-line NSCLC treatment, which could attract interest from both investors and pharmaceutical partners. Such outcomes may support future financing initiatives or collaborations, given the pressing market need for more effective cancer therapies.

Investors should monitor upcoming data releases slated for 2025, which could refine insights into the therapy's safety and long-term efficacy. The demonstrated 24-month OS rate of 81.0% raises the stakes, underscoring the potential commercial viability of efti in an increasingly competitive market for immunotherapy products.

Given the preliminary efficacy data, investors might consider a strategic position in Immutep’s stock, factoring in potential volatility leading up to and following further data announcements. Long-term holders may benefit from a bullish sentiment as trial milestones are achieved. However, with the biotech sector's inherent risks—primarily regulatory and commercial uncertainties—investors should maintain a cautious but optimistic approach, weighing these compelling clinical results against broader market conditions.

In summary, patience may yield rewards for investors as the insights from INSIGHT-003 unfold, shaping Immutep's growth trajectory. Engaging in active monitoring of trial outcomes and market reactions will be key to maximizing investment potential.